IntegraGen announced that it presented data on several proprietary microRNA biomarkers during the 2018 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland. Based on an analysis of liquid biopsy samples from over 133 patients with advanced squamous cell carcinoma of the lung enrolled in the Lux-Lung 8 Phase III Clinical Trial, the data presented demonstrated that the expression of specific microRNAs in the serum can differentiate patient response to afatinib and erlotinib therapy and identify emergence of EGFR-TKI resistance during therapy.

Click here to view press release.

Attachments

  • Original document
  • Permalink

Disclaimer

IntegraGen SA published this content on 12 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 April 2018 06:11:30 UTC